- Home
- CELU vs ANVS Comparison
CELU vs ANVS Comparison
Compare CELU & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- ANVS
- Stock Information
- Founded
- CELU 2016
- ANVS 2008
- Country
- CELU United States
- ANVS United States
- Employees
- CELU N/A
- ANVS N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- ANVS Health Care
- Exchange
- CELU Nasdaq
- ANVS Nasdaq
- Market Cap
- CELU 42.2M
- ANVS 44.6M
- IPO Year
- CELU N/A
- ANVS 2020
- Fundamental
- Price
- CELU $3.03
- ANVS $2.69
- Analyst Decision
- CELU
- ANVS Strong Buy
- Analyst Count
- CELU 0
- ANVS 4
- Target Price
- CELU N/A
- ANVS $18.00
- AVG Volume (30 Days)
- CELU 491.2K
- ANVS 438.8K
- Earning Date
- CELU 05-08-2025
- ANVS 08-14-2025
- Dividend Yield
- CELU N/A
- ANVS N/A
- EPS Growth
- CELU N/A
- ANVS N/A
- EPS
- CELU N/A
- ANVS N/A
- Revenue
- CELU $54,220,000.00
- ANVS N/A
- Revenue This Year
- CELU $23.29
- ANVS N/A
- Revenue Next Year
- CELU N/A
- ANVS N/A
- P/E Ratio
- CELU N/A
- ANVS N/A
- Revenue Growth
- CELU 138.11
- ANVS N/A
- 52 Week Low
- CELU $1.00
- ANVS $1.11
- 52 Week High
- CELU $5.22
- ANVS $12.58
- Technical
- Relative Strength Index (RSI)
- CELU 71.05
- ANVS 56.73
- Support Level
- CELU $2.01
- ANVS $2.63
- Resistance Level
- CELU $2.66
- ANVS $2.89
- Average True Range (ATR)
- CELU 0.24
- ANVS 0.22
- MACD
- CELU 0.08
- ANVS 0.02
- Stochastic Oscillator
- CELU 91.67
- ANVS 82.42
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.